España
CASC
El viernes $heff parece que andaba pensando en lo mismo, porque comentaba en un twitt que iba a tocar ya entrada o algo similar.
NVIV
PixarBio Withdraws Offer for InVivo Therapeutics (NVIV)
«Después de nada, o después de todo/ supe que todo no era más que nada.»
CLSN
Colocación aún por especificar
We are offering shares of our common stock and base warrants to purchase shares of our common stock. Each share of our common stock is being sold together with a base warrant to purchase of a share of our common stock for a public offering price of $ per share and $ per base warrant. Each base warrant will have an exercise price per share equal to % of the last reported sale price of our common stock as of the close of the trading day immediately preceding the pricing of this offering, will be immediately exercisable and will expire on the fifth anniversary of the original issuance date. The shares of our common stock and base warrants are immediately separable and will be issued separately, but will be purchased together in this offering.
http://stocknewsflow.com/749647_000143774917000937_0001437749-17-000937ppp4
«Después de nada, o después de todo/ supe que todo no era más que nada.»
Y fuera de ACHN en even. Ninguna farma por el momento.
APTO
Menuda castaña.
A 0,95. 27% abajo
Si te sientas en la mesa y no descubres al "primo" es que lo eres tú.
Me preguntaron por APTO hace poco en ST un inversor de USA y le comenté que tenía visos de scam. No ha defraudado ;)
HZNP velas 1h
ven pa'ca'maja ;)
crsp
genoma
comenté que salió a bolsa y llegoó a los 25$ lleva perdiendo valor y frena en fibo zona 18 después de fuerte caída hoy, poco liquida, colaboraciones con Bayer y vertex
curar enfermedades a nivel molecular usando la tecnología de edición de genes revolucionaria llamada CRISPR / Cas9.
alto riesgo esto del genoma, parece?
http://crisprtx.com/our-programs/our-pipeline.php
http://www.bio-itworld.com/2017/1/9/interference-a-crispr-patent-dispute-roadmap.aspx
Following the Money: The Hunt for CRISPR Dollar Bills
To better understand and appreciate what's at stake in this patent litigation, there are a few things to know about CRISPR Therapeutics.
The first is that Emmanuelle Charpentier is one of the company's co-founders and sits on its scientific advisory board. As such, Charpentier has non-exclusively licensed her rights to her interests in the '859 patent application—and its affiliated patent applications—to CRISPR Therapeutics. Because these licenses form, more or less, the entire basis of the company's business model, a favorable USPTO ruling on behalf of the Broad in this patent interference case would be devastating for the company.
The same goes for Charpentier herself—and CRISPR Therapeutics is far from the only company with a directly vested interest in the outcome of these proceedings. According to a January 25, 2016, USPTO filing in her patent interference case, Charpentier has similarly licensed these patent application interests to two additional companies.
The first, ERS Genomics Ltd., was also co-founded by Charpentier and purports to hold an exclusive worldwide license to all of Charpentier's interests in the intellectual property rights covered by the '859 patent application for all applicable CRISPR/Cas9 uses other than those as a human therapeutic; to these ends, ERS apparently exists for the sole purpose of providing a vehicle to license Charpentier's CRISPR/Cas9 IP interests.
http://labiotech.eu/horizon-discovery-automated-crispr/
siquiente fibo 16 medios. y estaría cerca sobreventa rsi
Tus Canf
Entrada en 1.96 stop ajustado 1.94 1.93
Me recuerda psti y no me gusta.
